Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients

Clinical Nephrology

Volumn 78, Issue 3, 2012, Pages 181-188

  Fishbane, Steven ^a   Bolton, W Kline ^b   Winkelmayer, Wolfgang C ^c   Strauss, William ^d   Li, Zhu ^d   Pereira, Brian J G ^d  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMAG PHARMACEUTICALS INC   (United States)

Author keywords

Chronic kidney disease; Ferumoxytol; Intravenous iron; Iron deficiency anemia

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FERRO SEQUELS; FERROUS FUMARATE; FERUMOXYTOL; HEMOGLOBIN; IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE HEMOGLOBIN CONTENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANEMIA, IRON-DEFICIENCY; CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; FERUMOXYTOL; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETICULOCYTES; TRANSFERRIN;

EID: 84867663468     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107397     Document Type: Article

References (18)

1. Using iron agents. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47 (Suppl 3): S58-S70. doi:10.1 053/j.ajkd.2006.03.016
2. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4: 386-393. doi:10.2215/CJN.02840608 PubMed
3. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19: 1599-1605. doi:10.1681/ASN.2007101156 PubMed
4. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008; 52: 907-915. doi:10.1053/j.ajkd.2008.08.001 PubMed
5. Feraheme Prescribing Information. Lexington, Ma 2009.
6. Data on File. Lexington, MA: AMAG Pharmaceuticals, Inc.2007.
7. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009; 4: 57-61. doi:10.2215/CJN.01670408 PubMed
8. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006; 19: 161-167. PubMed
9. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984. doi:10.1681/ASN.2006091034 PubMed
10. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. doi:10.1056/NEJMoa065485 PubMed
11. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. doi:10.1056/NEJMoa062276 PubMed
12. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590. doi:10.1056/ NEJM199808273390903 PubMed
13. EPOGEN® Prescribing Information. Thousand Oaks, CA 2008 March 2008.
14. PROCRIT (epoetin alfa) For Injection. Thousand Oaks, CA2008.
15. Aranesp (darbepoetin alfa) For Injection. Thousand Oaks, CA2008.
16. Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1 (Suppl 1): S9-S18. doi:10.2215/ CJN.01390406 PubMed
17. Coyne D. Iron indices: what do they really mean? Kidney Int Suppl. 2006; 69: S4-S8. doi:10.1038/ sj.ki.5000404 PubMed
18. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int. 2009; 75: 104-110. doi:10.1038/ ki.2008.526 PubMed